000836466 001__ 836466
000836466 005__ 20210129231010.0
000836466 0247_ $$2doi$$a10.1016/j.ejps.2017.07.015
000836466 0247_ $$2WOS$$aWOS:000407836700020
000836466 0247_ $$2Handle$$a2128/18656
000836466 0247_ $$2altmetric$$aaltmetric:22265612
000836466 0247_ $$2pmid$$apmid:28711713
000836466 037__ $$aFZJ-2017-05584
000836466 082__ $$a610
000836466 1001_ $$0P:(DE-Juel1)164354$$aElfgen, Anne$$b0$$ufzj
000836466 245__ $$aSurprisingly high stability of the Aβ oligomer eliminating all-d-enantiomeric peptide D3 in media simulating the route of orally administered drugs
000836466 260__ $$aNew York, NY [u.a.]$$bElsevier$$c2017
000836466 3367_ $$2DRIVER$$aarticle
000836466 3367_ $$2DataCite$$aOutput Types/Journal article
000836466 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1527083281_26354
000836466 3367_ $$2BibTeX$$aARTICLE
000836466 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000836466 3367_ $$00$$2EndNote$$aJournal Article
000836466 520__ $$aThe aggregation of the amyloid β protein (Aβ) plays an important role in the pathology of Alzheimer's disease. Previously, we have developed the all-d-enantiomeric peptide D3, which is able to eliminate neurotoxic Aβ oligomers in vitro and improve cognition in a transgenic Alzheimer's disease mouse model in vivo even after oral administration. d-Peptides are expected to be more resistant against enzymatic proteolysis compared to their l-enantiomeric equivalents, and indeed, a pharmacokinetic study with tritiated D3 revealed the oral bioavailability to be about 58%. To further investigate the underlying properties, we examined the stability of D3 in comparison to its corresponding all-l-enantiomeric mirror image l-D3 in media simulating the gastrointestinal tract, blood and liver. Potential metabolization was followed by reversed-phase high-performance liquid chromatography. In simulated gastric fluid, D3 remained almost completely stable (89%) within 24 h, while 70% of l-D3 was degraded within the same time period. Notably, in simulated intestinal fluid, D3 also remained stable (96%) for 24 h, whereas l-D3 was completely metabolized within seconds. In human plasma and human liver microsomes, l-D3 was metabolized several hundred times faster than D3. The remarkably high stability may explain the high oral bioavailability seen in previous studies allowing oral administration of the drug candidate. Thus, all-d-enantiomeric peptides may represent a promising new compound class for drug development.
000836466 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000836466 7001_ $$0P:(DE-Juel1)133853$$aSantiago-Schübel, Beatrix$$b1$$ufzj
000836466 7001_ $$0P:(DE-Juel1)145165$$aGremer, Lothar$$b2$$ufzj
000836466 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b3$$ufzj
000836466 7001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b4$$eCorresponding author$$ufzj
000836466 773__ $$0PERI:(DE-600)1483522-8$$a10.1016/j.ejps.2017.07.015$$p203-207$$tEuropean journal of pharmaceutical sciences$$v107$$x0928-0987$$y2017
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.pdf$$yRestricted
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.pdf$$yPublished on 2017-07-12. Available in OpenAccess from 2018-07-12.
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.gif?subformat=icon$$xicon$$yPublished on 2017-07-12. Available in OpenAccess from 2018-07-12.
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.jpg?subformat=icon-1440$$xicon-1440$$yPublished on 2017-07-12. Available in OpenAccess from 2018-07-12.
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.jpg?subformat=icon-180$$xicon-180$$yPublished on 2017-07-12. Available in OpenAccess from 2018-07-12.
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.jpg?subformat=icon-640$$xicon-640$$yPublished on 2017-07-12. Available in OpenAccess from 2018-07-12.
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/Elfgen%20et%20al.%202017.pdf?subformat=pdfa$$xpdfa$$yPublished on 2017-07-12. Available in OpenAccess from 2018-07-12.
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.gif?subformat=icon$$xicon$$yRestricted
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.jpg?subformat=icon-1440$$xicon-1440$$yRestricted
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.jpg?subformat=icon-180$$xicon-180$$yRestricted
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.jpg?subformat=icon-640$$xicon-640$$yRestricted
000836466 8564_ $$uhttps://juser.fz-juelich.de/record/836466/files/1-s2.0-S0928098717304141-main.pdf?subformat=pdfa$$xpdfa$$yRestricted
000836466 909CO $$ooai:juser.fz-juelich.de:836466$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000836466 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)164354$$aForschungszentrum Jülich$$b0$$kFZJ
000836466 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)133853$$aForschungszentrum Jülich$$b1$$kFZJ
000836466 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)145165$$aForschungszentrum Jülich$$b2$$kFZJ
000836466 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b3$$kFZJ
000836466 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b4$$kFZJ
000836466 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000836466 9141_ $$y2017
000836466 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000836466 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000836466 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000836466 915__ $$0StatID:(DE-HGF)0530$$2StatID$$aEmbargoed OpenAccess
000836466 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEUR J PHARM SCI : 2015
000836466 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000836466 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000836466 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000836466 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000836466 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000836466 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000836466 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000836466 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000836466 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000836466 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000836466 920__ $$lyes
000836466 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie $$x0
000836466 9201_ $$0I:(DE-Juel1)ZEA-3-20090406$$kZEA-3$$lAnalytik$$x1
000836466 9801_ $$aFullTexts
000836466 980__ $$ajournal
000836466 980__ $$aVDB
000836466 980__ $$aUNRESTRICTED
000836466 980__ $$aI:(DE-Juel1)ICS-6-20110106
000836466 980__ $$aI:(DE-Juel1)ZEA-3-20090406
000836466 981__ $$aI:(DE-Juel1)IBI-7-20200312